Back to GetFilings.com

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

For the Quarterly period ended November 30, 2004

For the transition period from              to             

Commission File No. 0-12240

BIO-LOGIC SYSTEMS CORP.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s Telephone Number, Including Area Code (847-949-5200)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report): not applicable

Indicate by check x whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES  x    NO  ¨

Indicate by check x whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    YES  ¨    NO  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Table of Contents

TABLE OF CONTENTS

2

Table of Contents

Part 1. Financial Information

Item 1. Financial Statements

Bio-logic Systems Corp.

Condensed Consolidated Balance Sheets

(Unaudited)

(In Thousands)

The accompanying notes are an integral part of these statements.

3

Table of Contents

Bio-logic Systems Corp.

Condensed Consolidated Statement of Operations and Retained Earnings

(Unaudited)

(In Thousands, Except Per Share Data)

The accompanying notes are an integral part of these statements.

4

Table of Contents

Bio-logic Systems Corp.

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(In Thousands)

The accompanying notes are an integral part of these statements.

5

Table of Contents

Bio-logic Systems Corp. and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

(Unaudited)

These unaudited interim condensed consolidated financial statements of Bio-logic Systems Corp. (the “Company,” “we” or “us”) were prepared under the rules and regulations for reporting on Form 10-Q. Accordingly, we omitted some information and footnote disclosures normally accompanying the annual financial statements. You should read these interim financial statements and notes in conjunction with our audited consolidated financial statements and their notes included in our Annual Report on Form 10-K for the fiscal year ended February 29, 2004, as filed with the Securities and Exchange Commission on June 1, 2004 (the “Annual Report”). In our opinion, the unaudited condensed consolidated financial statements include all adjustments necessary for a fair statement of the results of operations, financial position and cash flows for the interim periods. All adjustments were of a normal recurring nature. Operating results for the three and nine months ended November 30, 2004 are not necessarily indicative of the results that may be expected for the fiscal year ending February 28, 2005. For additional information, refer to the Annual Report.

Consolidation - The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned domestic subsidiaries, Neuro Diagnostics, Inc. and Bio-logic International Corp., and its wholly-owned foreign subsidiary, Bio-logic Systems Corp., Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents - Cash equivalents include all highly liquid investments purchased with average maturities of three months or less.

Accounts Receivable - The majority of the Company’s accounts receivable are due from companies in the medical and health care industries. Credit is extended based on evaluation of a customer’s financial condition. New non-institutional customers are generally subject to a deposit. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts, and are generally due within 30 days for domestic customers and 60 days for international customers. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due and the Company’s previous loss history. The Company writes off accounts receivable when they are determined to be uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. Charges for doubtful accounts are recorded in selling, general and administrative expenses.

Inventories - Inventories consist principally of components, parts and supplies, and are stated at the lower of cost, determined by the First-in, First-out method, or market. Inventories (in thousands) consist of the following:

Property, Plant and Equipment - Property, plant and equipment are stated at cost. The cost of maintenance and repairs is charged to income as incurred, and significant renewals and betterments are capitalized. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three years to forty years.

Intangible Assets - Intangible assets consist primarily of capitalized software costs for research and development, as well as certain patent, trademark and license costs. Capitalized software development costs are recorded in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 86, “Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed,” with costs being amortized using the straight-line method over a five-year period.

Patent, trademark and license costs are amortized using the straight-line method over their estimated useful lives of five years. On an ongoing basis, management reviews the valuation of intangible assets to determine if there has been impairment by comparing the related assets’ carrying values to the undiscounted estimated future cash flows and/or operating income from related operations.

6

Table of Contents

The following table (in thousands) summarizes the components of gross and net intangible asset balances:

Long-Lived Assets – The Company regularly reviews long-lived assets for impairment in accordance with SFAS No. 144, “Accounting for the Impairment of Long-Lived Assets.” No impairment was realized for the nine-month periods ended November 30, 2004 and 2003.

Other Assets – Other assets consist mainly of long-term trade receivables and capitalized costs associated with business development activities. Any required reserves for long-term trade receivables are recorded as part of the Allowance for Doubtful Accounts; there are currently no reserve requirements.

Other Receivables – Other receivables at February 29, 2004 consisted of a medical claim receivable that was collected during fiscal 2005.

Revenue Recognition – The Company derives revenue from the sales of electrodiagnostic systems, disposable supplies, extended warranty contracts, non-warranty repair, and governmental research and development “grants.” With the exception of domestic customers associated with certain group purchasing contracts, the terms of sale for systems and related supplies are generally FOB shipping point.

Domestically, the Company sells its neurology and sleep systems through a direct sales force, and uses a dealer network to sell its hearing screening and diagnostic systems; internationally, the entire line of electrodiagnostic systems and supplies is sold through distributors located in various countries. There is no general right for a customer, dealer or distributor to return product. All sales are final, regardless of the distribution channel; returns are rare and are usually done due to order error or quality reasons.

The Company recognizes revenue when it is realized or realizable and earned, in accordance with Statement of Position No. 97-2, “Software Revenue Recognition”; specifically, when there is persuasive evidence of an arrangement, delivery has occurred, the sales price is fixed or determinable, and collectibility is reasonably assured. Set-up and training revenue related to system sales is not recognized until the service is completed. Revenue from the performance of non-warranty repair activities is recognized in the period in which the work is performed. Revenue from extended warranty contracts is recognized over the life of the warranty.

Revenue from research and development contracts relate to governmental grants awarded by the National Institute of Health. The grant covers reimbursement of specific expenses related to the feasibility and development of projects for which the grants were given, and the Company recognizes revenue in the same period the qualifying costs are incurred. The Company’s obligation is to perform these feasibility and development activities in accordance with the terms of the grant, with no obligation for the work to result in a successful outcome such as a new product or successful discovery.

The Company carries a sales reserve that reduces revenue for potential future product returns as well as unperformed set-up and training, and reviews its adequacy quarterly. To date, this reserve has been insignificant.

Royalties and Intangible Amortization Expenses – Royalty expenses and the amortization of intangibles are recorded as part of product cost.

Advertising – Advertising costs are expensed as incurred.

Research and Development Costs – Research and development (R&D) costs are expensed as incurred. Capitalized research and development costs reflect internally-generated software development costs associated with bringing new products to market, or significantly adding new features and functions to existing products. We account for the capitalization of software development costs in accordance with SFAS No. 86, “Accounting for the Costs of Computer Software to Be Sold, Leased, Or Otherwise Marketed;” specifically: (a) R&D costs incurred in determining technological feasibility are expensed; (b) all material costs from the point where technological feasibility is determined up to the point when the product is available for general release to customers are capitalized; and (c) capitalization ceases when the developed product is available for general release to customers.

7

Table of Contents

Income Taxes - Deferred tax assets and liabilities are computed quarterly for differences between financial statement basis and tax basis of assets and liabilities using enacted tax rates for the years in which the differences are expected to become recoverable. A valuation allowance is established where necessary to reduce deferred tax assets to the amount expected to be realized.

Deferred federal income taxes are not provided for the undistributed earnings of the Company’s foreign subsidiary. Undistributed foreign earnings were $2,479,830 and $2,876,107 as of November 30 and February 29, 2004, respectively.

Use of Estimates - In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments - The Company’s financial instruments include cash equivalents, accounts receivable, and accounts payable. The carrying value of cash equivalents, accounts receivable and accounts payable approximate their fair value because of the short-term nature of these instruments.

Shipping and Handling Costs - In accordance with Emerging Issues Task Force 00-10, “Accounting for Shipping and Handling Fees and Costs,” the Company has reflected billings to customers for freight and handling as net sales and associated freight-out as cost of sales.

Stock-Based Compensation - The Company maintains a stock incentive plan. The Company accounts for this plan under the recognition and measurement principles of Accounting Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. No compensation costs are recognized for stock option grants. All options granted under the Company’s plan have an exercise price equal to or greater than the market value of the underlying common stock on the date of grant.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 123, “Accounting for Stock-Based Compensation,” to stock-based compensation:

Dollar amounts in the following discussion are in thousands except for per share amounts.

Earnings per Share – Basic earnings per share is based on the weighted average number of shares outstanding during the year. Diluted earnings per share is based on the combination of weighted average number of shares outstanding and dilutive potential shares, which totaled 4,632,981 and 4,588,571 for the Fiscal 2005 Third Quarter and the Fiscal 2005 Nine Months, respectively.

8

Table of Contents

Comprehensive Income - SFAS No. 130, Reporting Comprehensive Income, requires disclosure of the components of and total comprehensive income in the period in which they are recognized in the financial statements. Comprehensive income is defined as the change in equity (net assets) of a business enterprise arising from transactions and other events and circumstances from non-owner sources. It includes all changes in stockholders’ equity during the reporting period except those resulting from investments by owners and distributions to owners. The Company does not have changes in stockholders’ equity other than those resulting from investments by and distributions to owners. The functional currency for the Company’s international operations is the U.S. dollar.

Segment, Customer and Geographic Information - SFAS No. 131 requires disclosures of certain segment information based on the way management evaluates segments for making decisions and assessing performance. It also requires disclosure of certain information about products and services, the geographic areas in which the Company operates and major customers. We operate in two business segments within the health care field: computerized medical electro-diagnostic products and systems, and related supplies, warranty, service and repair.

Revenue (in thousands) from customers by segment is as follows:

Revenue (in thousands) from customers by geographic area is as follows:

For the fiscal quarters ended November 30, 2004 and 2003, there were no sales to a single customer that accounted for greater than 10% of revenue.

Long-lived assets include fixed assets (property, plant and equipment) and intangible assets. The Company has fixed assets in the United States and overseas; all intangible assets are domiciled in the United States. Long-lived assets by country, net of accumulated depreciation and amortization, are as follows (in thousands):

Contingency - On April 22, 2004, two plaintiffs filed a product liability claim against us and certain other defendants seeking specific damages of $12,300,000, as well as unspecified damages for future loss of income earning capacity. A brief description of this lawsuit may be found in Part II, Item 1 to this Form 10-Q. We intend to vigorously defend against the claims brought before us in this suit.

9

Table of Contents

Although the outcome of any litigation is inherently uncertain, we believe that our product liability insurance coverage is adequate to cover liabilities resulting from this litigation, including defense costs and out of pocket expenses, and therefore the results of this litigation should not have a material adverse effect on our business, assets, financial condition, liquidity and results of operations.

Recent Accounting Pronouncements

In December 2004, the Financial Accounting Standards Board (“FASB”) revised SFAS No. 123, “Accounting for Stock Based Compensation.” SFAS No. 123-Revised (“SFAS No. 123-R”) supercedes APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations, and will require all companies to estimate the fair value of incentive stock options granted and then amortize that estimated fair value to expense over the options’ vesting periods. SFAS No. 123-R is effective for all periods beginning after June 15, 2005. The Company currently accounts for its stock option plans under the recognition and measurement principles of APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. No employee or outside director compensation costs related to stock option grants are currently reflected in net income, as all option awards granted under those plans had an exercise price equal to or greater than the market value of the underlying common stock on the date of grant. The Company is required to adopt SFAS No. 123-R by the third quarter of Fiscal 2006. The section titled “Stock-Based Compensation” disclosed earlier in these notes shows pro forma information as if the Company had elected to adopt the requirements of the previously issued SFAS No. 123. The Company is currently determining the extent to which the adoption of SFAS No. 123-R will have on its results of operations or financial position.

Reclassifications - Certain reclassifications were made to fiscal 2004 amounts to conform to current year financial presentation.

10

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933, that reflect our current expectations about our future results, performance, prospects and opportunities. These forward-looking statements are subject to significant risks, uncertainties, and other factors, including those identified in Exhibit 99.1, “Risk Factors”, filed with this Form 10-Q, which may cause actual results to differ materially from those expressed in, or implied by, any such forward-looking statements. The forward-looking statements within this Form 10-Q may be identified by words such as “believes,” “anticipates,” “expects,” “intends,” “may,” “would,” “will” and other similar expressions. These words are not, however, the exclusive means of identifying these statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances occurring subsequent to the filing of this Form 10-Q with the SEC or for any other reason. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. The following discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and the Notes to the Unaudited Condensed Consolidated Financial Statements in Part I, Item 1 to this Form 10-Q, and the audited consolidated financial statements and their notes included in our Annual Report on Form 10-K for the fiscal year ended February 29, 2004, as filed with the Securities and Exchange Commission on June 1, 2004 (the “Annual Report”).

Overview

We are a healthcare technology company operating in two segments: computerized medical electro-diagnostic products and systems; and related supplies, warranty, service and repair. Our customers are generally hospitals, clinics, universities and physicians. Our systems conduct tests that are typically used by medical practitioners to aid in the diagnosis of certain neurological disorders, brain disorders and tumors, sensory disorders, sleep disorders, and hearing loss (including audiological and hearing screening and diagnosis).

Our electro-diagnostic products and systems segment accounted for 72% of our total net sales in the fiscal quarter ended November 30, 2004; historical contributions of this segment to our total net sales are generally between 70% and 75%. System sales typically represent capital expenditures on the part of our customers. The demand in the United States for initial hearing screening products in hospitals has declined from the prior year due to market saturation; sales in this market are more replacement in nature. However, we have experienced sales growth of these products in alternate markets. Our focus for domestic hearing systems relate to the diagnosis of babies referred for further testing after initial screening. Our M^.A^.S^.T^.E^.R^™ diagnostics product offering has gained strong acceptance by audiologists for aiding in the determination of appropriate therapies to benefit the infant. Also, during the third quarter of Fiscal 2005 we began shipping new software (CHAMP) that assists audiologists in detecting Meniere’s Disease, an affliction that affects over 2.6 million Americans. Meniere’s Disease is characterized by attacks of vertigo, fluctuating hearing loss, ringing in the ear (tinnitus) and a sense of fullness in the ear. The EEG market for short-term and long-term monitoring is essentially flat, with significant competition from a feature and technology point of view. Our sleep diagnostic products and systems target the growing market for sleep apnea monitoring. Earlier this year, we introduced the VISION^™ product line, which adds several competitive features to both our EEG and sleep monitoring products, and has had favorable initial acceptance in the marketplace, especially in the sleep monitoring area. The timing of system sales can be affected by many factors, including product features, pricing, order size (especially for neurology system sales to hospitals), customers’ trial periods and approval processes, and the hospital or medical practitioners’ capital availability. These factors can materially impact revenues and earnings from one quarter to the next.

Our supplies, warranty, service and repair segment sells disposable products to our installed customer base as well as to owners of our competitors’ systems. Certain proprietary hearing products such as the Ear Muffin^™ and the HALO Ear Muffin (the “HALO”) transducers are the basis for much of the revenue and profit growth in this segment. The HALO was introduced earlier this year and has experienced favorable initial acceptance. We experience intense competition related to our Ear Muffin and HALO products, which are designed for use on Bio-logic’s systems, as well as for use as an equivalent product to replace the Natus^® EarCoupler^® and Flexicoupler^® disposables. In addition to the one-year warranty that is provided as part of purchasing our electro-diagnostic systems, we offer our customers extended warranties up to five years. We also generate revenue by servicing and repairing customer systems that are out of warranty. Finally, a small part of our revenue is generated from governmental research grants.

Critical Accounting Policies and the Use of Estimates

Our “critical accounting policies” are those that require application of management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain and may change in future periods. They are not intended to be a comprehensive list of all of our significant accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles, with no need for management’s judgment in their application. There are also areas in which the selection of an available alternative policy would not produce a materially different result. We have identified the following as our critical accounting policies: revenue recognition, inventory valuation and the capitalization of software costs.

11

Table of Contents

Revenue Recognition

We recognize revenue when it is realized or realizable and earned, in accordance with Statement of Position No. 97-2, “Software Revenue Recognition;” specifically, when there is persuasive evidence of an arrangement, delivery has occurred, the sales price is fixed or determinable, and collectibility is reasonably assured. Set-up and training revenue related to system sales is not recognized until the service is completed. With the exception of domestic customers associated with certain group purchasing contracts, the terms of sale for systems and related supplies are generally FOB shipping point. Revenue from the performance of non-warranty repair activities is recognized in the period in which the work is performed. Revenue from extended warranty contracts is recognized over the life of the warranty. All sales are final; there is no general right for a customer, dealer or distributor to return our products. Any exception regarding product returns requires senior management approval. A small sales reserve exists to cover potential future product returns, as well as unperformed set-up and training.

We also maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. This estimate is based on historical experience, current economic and industry conditions, and the financial condition of our customers. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

Inventory Valuation

Inventories consist principally of components, parts, supplies and demonstration equipment, are valued at the lower of cost or market, and include materials, labor and manufacturing overhead. We write down inventory for estimated obsolescence and for unmarketability, equal to the difference between the cost of the inventory and its estimated market value, based on assumptions about future demand and market conditions. If future demands or market conditions were to be less favorable than what was projected, additional inventory write-downs may be required. Due to the proprietary nature of many of our raw materials and components, we generally do not sell excess or obsolete inventory to third parties. Demonstration inventory is sold at a discount, thus generating similar margins to new systems sold.

Capitalization of Software Costs

Capitalized software costs for research and development are amortized over a five-year period. On an ongoing basis, management reviews the valuation of these software costs to determine if there has been impairment to the carrying value of these assets, and adjusts this value accordingly.

Other significant accounting policies, not involving the same level of measurement uncertainties as those discussed above, are nevertheless important to an understanding of the financial statements. Policies relating to fair value of financial instruments, depreciation, and income taxes require judgments on complex matters that are often subject to multiple external sources of authoritative guidance such as the Financial Accounting Standards Board and the Securities and Exchange Commission.

Dollar amounts in the following discussion are in thousands except for per share amounts.

Results of Operations

Net Sales

Net sales for the three month period ended November 30, 2004 (the “Fiscal 2005 Third Quarter”) were $7,765, a 12% increase from $6,962 in the three month period ended November 30, 2003 (the “Fiscal 2004 Third Quarter”). Net sales for the nine month period ended November 30, 2004 (the “Fiscal 2005 Nine Months”) were $22,257, a 10% increase from $20,208 in the nine month period ended November 30, 2003 (the “Fiscal 2004 Nine Months”).

Domestic sales for the Fiscal 2005 Third Quarter, which include sales to Canada, were $6,383, or 82% of net sales. This represents a 14% increase from $5,617, or 81% of net sales, from the Fiscal 2004 Third Quarter. Domestic electro-diagnostic products and systems sales increased 14% in the Fiscal 2005 Third Quarter over the Fiscal 2004 Third Quarter. Our Sleepscan product line sales increased significantly from the Fiscal 2004 Third Quarter, primarily due to the introduction of our new VISION product offering which improved our competitive advantage in sleep monitoring. Sales of our hearing screening and diagnostic products also increased in the Fiscal 2005 Third Quarter over the Fiscal 2004 Third Quarter. These increases were partially offset by sales declines in our EEG monitoring product line.

12

Table of Contents

Supplies, warranty, service and repair sales increased 13% domestically over the Fiscal 2004 Third Quarter, primarily due to the acceptance of our HALO transducer introduced earlier in the year, and to the increase in our customer base using the HALO as a result of our customer conversion efforts. These increases were offset by reductions in our governmental contract revenue due to the conclusion of certain research studies supported by governmental grants.

Domestic sales (including sales to Canada) for the Fiscal 2005 Nine Months, representing 83% of net sales, increased 12% to $18,383 compared to $16,455 for the Fiscal 2004 Nine Months. Increases in electro-diagnostic system were led by sleep monitoring systems related to the introduction of our VISION product offering, and by hearing screening and diagnostic sales. Supplies, warranty, service and repair sales were also higher, led by increased sales of disposable products, mainly of our Ear Muffin and HALO products, partly offset by reductions in governmental contract revenue related to the conclusion of research grants.

Foreign sales for the Fiscal 2005 Third Quarter, representing 18% of the Company’s net sales, increased 3% to $1,382 from $1,345 in the Fiscal 2004 Third Quarter. For the Fiscal 2005 Nine Months, foreign sales represented 17% of net sales, and increased 3% to $3,874, compared to $3,753 for the Fiscal 2004 Nine Months. For the Fiscal 2005 Third Quarter, sales growth in both the hearing diagnostics area, where our Navigator^® Pro product line with our M^.A^.S^.T^.E^.R technology continues to gain international acceptance, and in our epilepsy monitoring area, helped to offset sales reductions in hearing screening systems. Although for the Fiscal 2005 Nine Months, foreign sales of the Company’s electro-diagnostic systems were essentially flat, significant sales increases of our Navigator Pro hearing diagnostic systems over the Fiscal 2004 Nine Months were offset by sales declines in our hearing screening systems and our sleep, EEG and epilepsy monitoring systems. Supplies, warranty, service and repair sales also increased, led by increased sales of disposable products, mainly of our Ear Muffin and HALO products.

Cost of Sales

Cost of sales for the Fiscal 2005 Third Quarter was $2,775, compared to $2,431 for the Fiscal 2004 Third Quarter. Cost of sales as a percentage of net sales was 36% in the Fiscal 2005 Third Quarter and 35% in the Fiscal 2004 Third Quarter, due primarily to shifts in product mix within electro-diagnostic products and systems, offset in part by decreases in inventory reserves. Cost of sales increased to $7,542 for the Fiscal 2005 Nine Months compared to $6,746 for the Fiscal 2004 Nine Months, due primarily to volume changes, partially offset by decreases in subcontractor installation services and inventory reserves. Cost of sales as a percentage of net sales was 34% for the Fiscal 2005 Nine Months and 33% for the Fiscal 2004 Nine Months, again due to mix changes within the electro-diagnostic products and systems.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses for the Fiscal 2005 Third Quarter were $3,183, $265 higher than the $2,918 recorded for the Fiscal 2004 Third Quarter. This increase in SG&A expenses was primarily due to higher selling expenses related to improved sales, and to increased professional services, bad debt provisions and payroll-related expenses, partly offset by a reduction in the provision for medical plan expenses, and in fees for tax services. As a percentage of net sales, however, SG&A expenses were 41% for the Fiscal 2005 Third Quarter, as compared to 42% for the Fiscal 2004 Third Quarter. SG&A expenses increased $650 to $9,518 for the Fiscal 2005 Nine Months compared to $8,868 for the Fiscal 2004 Nine Months, due primarily to higher expenses associated with increased sales, and increased professional services, bad debt provisions and payroll-related expenses, partly offset by reductions in customer seminar expenses, fees for tax services, and in the provision for medical plan expenses.

Our management initiated a review of our internal controls, as is required by Section 404 of the Sarbanes-Oxley Act of 2002, during the Fiscal 2005 Three Months. To date, we have incurred approximately $70 in professional services expenses in connection with the Section 404 review process, contributing to the increased levels of SG&A expenses we experienced both in the Fiscal 2005 Third Quarter and in the Fiscal 2005 Nine Months.

Research and Development Expenses

Research and development (“R&D”) expenses for the Fiscal 2005 Third Quarter were $1,094, compared to $1,000 recorded for the Fiscal 2004 Third Quarter. As a percentage of net sales, R&D expenses were 14% for both the Fiscal 2005 Third Quarter and the Fiscal 2004 Third Quarter. The increase in R&D expenses was primarily due to higher bonus provisions and payroll-related expenses, and an increased investment in software development costs both domestically and abroad, partly offset by a reduction in consulting expenses associated with governmental grant activities and increases in the portion of software development costs that are being capitalized. R&D expenses increased $229 to $3,372 for the Fiscal 2005 Nine Months compared to $3,143 for the Fiscal 2004 Nine Months. R&D expenses represented 15% of net sales for the Fiscal 2005 Nine Months and 16% for the Fiscal 2004 Nine Months. The increased R&D expense again was due to higher bonus provisions and payroll-related expenses, and increased investment in our product development, partly offset by a reduction in consulting expenses and increases in the portion of software development costs that are being capitalized.

13

Table of Contents

Operating Income

We had operating income in the Fiscal 2005 Third Quarter of $713, compared to $613 for the Fiscal 2004 Third Quarter. The increase was due primarily to higher gross profit partly offset by increased SG&A and R&D expenses. Operating income for the Fiscal 2005 Nine Months was $1,825 compared to $1,451 for the Fiscal 2004 Nine Months, again due to increased gross profit partly offset by increases in SG&A and R&D expenses.

Interest Income

Net interest income for the Fiscal 2005 Third Quarter decreased to $26 from $39 for the Fiscal 2004 Third Quarter, primarily driven by interest expenses associated with various historical tax obligations. Net interest income for the Fiscal 2005 Nine Months was $78, compared to $77 for the Fiscal 2004 Nine Months.

Income Tax

Income tax expense was $67 and $415 for the Fiscal 2005 Third Quarter and the Fiscal 2005 Nine Months, respectively, or 9% and 22%, respectively, of pretax income. Income tax expense was $70 and $274 for the Fiscal 2004 Third Quarter and the Fiscal 2004 Nine Months, respectively, or 11% and 18%, respectively, of pretax income. We reduced our accrual for income taxes in the Fiscal 2005 Third Quarter related to the closure of tax years for which these provisions were initially established. The Company’s income tax rate reflects the combination of federal and state effective tax rates, adjusted for the favorable impact of deferred tax assets and estimated tax credits.

Net Income

Net income for the Fiscal 2005 Third Quarter was $672, compared to $582 for the Fiscal 2004 Third Quarter. Diluted earnings per share (“EPS”) for the Fiscal 2005 Third Quarter was $0.15, compared to $0.13 per diluted share for the Fiscal 2004 Third Quarter. The increase in EPS was due to higher pretax income, partially offset by an increase in the number of outstanding shares.

Liquidity and Capital Resources

As of November 30, 2004, we had working capital of $18,262, a $1,550 increase from a working capital balance of $16,712 at February 29, 2004. Total cash and cash equivalents increased $2,287, from $12,750 at February 29, 2004 to $15,037 at November 30, 2004.

Cash Provided by Operating Activities

Net cash provided by operating activities for the nine months ended November 30, 2004 was $2,688 compared to $1,692 for the nine months ended November 30, 2003. This increase was primarily due to a decrease in accounts receivable related to improved collections, decreases in deferred tax provisions, and increases in accounts payable balances. These sources of cash flows were partly offset by replenishments of inventory levels.

Net inventory at November 30, 2004 was $2,308, a $400 increase from the February 29, 2004 level of $1,908. The increased shipment activity that occurred in the fourth quarter of fiscal 2004 reduced inventory levels below sustainable levels, and we increased our inventory levels to replenish our operating stock. We manage inventory by using a metric of days inventory on hand (DIOH), which relates the dollar amount of ending inventory levels to the amount of cost of sales that it generated. DIOH as of November 30, 2004 was 81 days, up from 77 days at the end of fiscal 2004.

Net accounts receivable at November 30, 2004 was $5,749, a decrease of $530 from the February 29, 2004 level of $6,279. This reduction was principally driven by collections during the first quarter of fiscal 2005 related to receivables generated due to a higher level of sales during the fourth quarter of fiscal 2004. We manage our receivables through the use of two key metrics: (1) days sales outstanding (“DSO”) and (2) the amount of customer account balances that are over 90 days past due. DSO allows us to analyze changes in our receivables balance as a function of the sales that generated that balance, rather than simply looking at the dollar change in the receivables account on a standalone basis. We use the exhaustion method to calculate DSO, which assumes that the receivables balance was generated from the most recent sales. Using this methodology, our DSO at November 30, 2004 was 63 days, a two-day increase from our DSO of 61 days at February 29, 2004. Our other receivables measurement of past due balances greater than 90 days is indicative of the potential risk to us of the existence of uncollectible accounts that could exist in our receivables balances. At November 30, 2004, our past due receivables balances greater than 90 days decreased over 30% from the February 29, 2004 level.

14

Table of Contents

Cash Used in Investing Activities

Net cash used in investing activities for the Fiscal 2005 Nine Months was $616, compared to net cash flows used in investing activities of $166 for the Fiscal 2004 Nine Months. Our fiscal 2005 use of cash was driven by increased capital spending, increases in the level of capitalized software development costs associated with our neurology products, and the capitalization of costs related to business development activities. These uses were partly offset by the collection of a $526 receivable related to a medical claim that was settled during the second quarter of Fiscal 2005.

Cash Flows Provided by Financing Activities

Net cash flows provided by financing activities for Fiscal 2005 Nine Months were $215, compared to $14 for the Fiscal 2004 Nine Months, related to the exercise of stock options.

We believe available cash balances and cash flows from operations will satisfy the liquidity and capital requirements of our current operations for the foreseeable future.

From time to time, we explore various corporate finance transactions such as business combinations or acquisitions, certain of which may include the issuance of our securities.

Recent Litigation

On April 22, 2004, two plaintiffs filed a product liability claim against us and certain other defendants seeking damages. A brief description of this lawsuit may be found in Part II, Item 1 to this Form 10-Q. Please also see the disclosure in Exhibit 99.1, “Risk Factors” under the caption “Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages and an increase in our insurance rates.”

Recent Developments

On January 7, 2005, Bio-logic’s Board of Directors declared a three-for-two stock split on its Common Stock, to be effected as a 50 percent stock dividend. The new shares and cash payments in lieu of fractional shares will be distributed on February 11, 2005, to stockholders of record on January 26, 2005. As a result of the split, stockholders will receive one additional share of Common Stock for every two shares owned on January 26, 2005. Cash payments in lieu of fractional shares will be based on the closing price of the Common Stock on the record date.

15

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our cash and variable-rate short-term cash equivalents are sensitive to changes in interest rates. Interest rate changes would result in a change in interest income. At current investment levels, our annual results of operations and statement of financial condition would vary by approximately $150,000 for every 1% change in our short-term interest rate. Exchange rate risk is not material for us. Less than US$25,000 resides in accounts denominated in foreign currency. Also, virtually all of our sales transactions are denominated in United States dollars, essentially eliminating the impact of exchange rates on the carrying value of our assets. Finally, the United States dollar is our functional currency for our Israeli operation, so there is no transaction or translation exchange rate concerns with that operation.

Item 4. Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Corporate Controller, of the design and operation of the Company’s disclosure controls and procedures. Based on this evaluation, the Company’s Chief Executive Officer and Corporate Controller concluded that, as of November 30, 2004, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed in the reports the Company files or submits under the Securities Exchange Act of 1934 (a) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Corporate Controller, as appropriate, to allow timely decisions regarding required disclosure.

Any control system, no matter how well designed and operated, can provide only reasonable (not absolute) assurance that its objectives will be met. Furthermore, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

There was not any change in the Company’s internal control over financial reporting that occurred during the quarterly period ended November 30, 2004 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

On April 22, 2004, Marcus L. Forsythe and Elizabeth Forsythe of Multnomah County, Oregon (the “Plaintiffs”) filed a Second Amended Complaint naming the Company as a defendant in a lawsuit against several parties that was filed in the Circuit Court of the State of Oregon for the County of Multnomah. The Plaintiffs allege that they have suffered damages as a result of auditory brain stem response and other related testing Mr. Forsythe underwent in April 2002 that was allegedly conducted, in part, using the Company’s Navigator Pro product. Plaintiffs seek to recover an aggregate of $12,300,000 in damages from the defendants for physical pain and suffering, emotional distress, the loss of past income and benefits, past and future medical, therapy, medication and household costs, and other foregone benefits, as well as unspecified damages for future loss of income earning capacity.

We intend to vigorously defend against the claims brought in the Forsythe litigation. Although the outcome of any litigation is inherently uncertain, we believe that our product liability insurance coverage is adequate to cover liabilities resulting from the Forsythe litigation including defense costs and out of pocket expenses, and therefore, that the Forsythe litigation should not have a material adverse effect on our business, assets, financial condition, liquidity and results of operations.

16

Table of Contents

Item 6. Exhibits

(a) Exhibits

17

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

18